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Abstract
Coated magnetite nanoparticles were linked to 68Ga complexes used in the positron emission tomography (PET) for a new tech-
nical approach to detect cancer tissue with radiopharmaceuticals. By substitution of the Ga isotope with an alpha emitter the same
compound could be used for cancer treatment. Furthermore the nanoparticles were connected to pH-sensitive complexes, enabling a
pH-controlled assembly/disassembly and therefore the spreading of the particles in the tissue. With this novel method of combining
detection and treatment simultaneously, the amount of medical exposure could be minimized for the patient. The results demon-
strate that magnetite nanoparticles can effectively be functionalized with PET isotopes and pH sensitive complexes in order to use
them as a new type of radiopharmaceuticals.
Introduction
In the field of diagnostic investigation of metabolic diseases
imaging methods based on nanotechnology have been recently
gaining more and more importance [1,2]. In the last 30 years the
positron emission tomography (PET) has acquired relevance
among the current conventional imaging methods such as
X-ray, computed tomography (CT) or magnetic resonance
imaging (MRI) [3]. PET gives insights in the metabolism of
living organisms and allows to detect diseases of neurological
or oncological origin [4,5]. It is a nuclear medicine imaging
technique that produces 3D images of functional processes in
the body. The circularly arranged system detects high energetic
γ-quanta, emitted indirectly via annihilation of a positron with
an electron by a radiopharmaceutical called “tracer” which has
been previously injected intravenously into the patient. A com-
puter reconstructs then tomographic images of the tracer con-
centration so that sectional images can be conveyed [5]. By
linking PET isotopes to magnetic nanoparticles (MNP)
a sophisticated system with different applications can be
achieved (Figure 1): The magnetism of the particles allows an
all-time control of the nanopharmaceuticals position, a linker,
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Figure 1: Model of a nanohybrid-PET-system. MNP can assemble and disassemble at different pH. The disassembled NP spread in the tumor cell
and can be detected by PET [6,7].
connecting the nanoparticles to each other, enables a pH-con-
trolled assembly/disassembly and the PET-isotopes provide a
detectable annihilation signal.
There are several isotopes that can be used in the PET: Besides
the mostly used isotopes namely 18F, 11C, 13N and 15O, 68Ga is
often used since it can be easily extracted by a 68Ge/68Ga
generator [5,6,8,9]. The 68Ga isotope is complexed for example
by a phosphonate containing chelate ligand and injected
into the body. The tracer enriches in the hydroxyapatite
(Ca10(PO4)6(OH)2) and can be used for investigations of the
bone metabolism [10-12]. Modifications of the functional
groups of the ligand enables the use of the Ga complex in a dif-
ferent way: PET-analogue Ga-DOTA (DOTA = 1,4,7,10-tetra-
azacyclododecane-1,4,7,10-tetraacetic acid) complexes were
synthesized and linked to Fe3O4 MNP. In this manner it is
possible to transport the PET tracer with an external magnetic
field right to the target location. The functionalized MNP are
linked to each other via [Fe(II)(bzimpy)2] (bzimpy =
2,6-bis(benzimidazol-2-yl)pyridine). The resulting MNP cluster
can be used as a pH-labile switch: By protonation of the elec-
tron pairs of the ligands (which are coordinated to the iron ion)
the MNP cluster-stabilizing complex [Fe(II)(bzimpy)2] decom-
poses [13] in an acidic environment such as the one present in
the cancer cell (Figure 1) [7,12]. Equipped with an alpha emitter
[14], they could initiate an apoptosis of the tumor cells. This
procedure may allow for combining diagnosis and therapy for
cancer diseases.
Results and Discussion
We synthesized magnetite nanoparticles through the well-estab-
lished co-precipitation method [15] and proceeded with further
functionalization to obtain biocompatible particles that can
assemble and disassemble by entering media with different pH
values. The resulting cave structure consists of three nanoparti-
cle units in every spatial direction. The accruing free space
inside the cave structure could be used to intercalate desirable
pharmaceuticals (Figure 2).
Beilstein J. Nanotechnol. 2016, 7, 121–125.
123
Figure 2: Idealized 3D cave structure of a NP cluster. Grey spheres:
MNP, lines: [Fe(II)(bzimpy)2] linking units, orange spheres: possible
intercalated molecules.
To reach a mutual conjunction we used silanized and amino-
functionalized MNP (1), which were dispersed for 4 h in an
ultrasonic bath at 80 °C in acetonitrile with Cl-bzimpy. The
deposit was then added to an iron(II) chloride tetrahydrate
solution and stirred for 2 h at 25 °C. DLS measurements
of the connected MNP (Figure 3 and Table 1) showed a
strong increase of the hydrodynamic diameter of the
[Fe(II)(bzimpy)2]-MNP (2) in comparison to the unsubstituted
MNP (+275 nm). It can hence be assumed that a network
(consisting of about three units in all spatial directions) of the
MNP was obtained. We assume that bigger cluster units do not
appear long enough to be detected due to shear forces
destroying them.
Figure 3: Diameter of the unsubstituted and networked MNP.
Table 1: Comparison of the hydrodynamic diameters.
compound hydrodynamic diameter [nm]
amine-MNP (1) 74.5
Fe(II)-(Cl-bzimpy)2-MNP (2) 349.8
Cl-bzimpy-MNP (3) 123.0
Ga-DOTA-MNP 141.2
The cluster units are stable in a pH range from 13 to 4.5. At
lower pH the clusters disassemble as anticipated and exhibit the
same hydrodynamic diameter as before. The TG/DTA measure-
ments of Cl-bzimpy-MNP (3) showed a weight loss of 2.9% in
the range between 30 and 100 °C caused by solvent molecules.
In the range from 100 to 500 °C the weight loss was 24.5%, so
that it can be assumed that the organic component bzimpy was
linked to the MNP (see Table 2).
Table 2: Comparison of weight loss during the TG/DTA measurement.
compound total organic weight loss [%]
amine-MNP (1) 4.3
Cl-bzimpy-MNP (3) 24.5
Ga-DOTA-MNP 46.1
In order to give the yield PET functionality to the MNP we
chose the DOTA chelator. It is highly preferred in medical
applications caused by the high stability of various metal
ion–DOTA complexes [16]. In this study we used a non-
radioactive Ga isotope as a proof of principle due to its same
chemical behavior compared to the radioactive isotopes of Ga.
By simply using unmodified DOTA and solving it in heated
dimethylformamide (DMF) we can use standard coupling
reagents for the functionalization of the MNP. By a high
amount of solvent the connection of the MNP to each other
caused by two carbon acid groups of the DOTA is prevented.
The conjunction of the Ga-DOTA complex with the MNP was
performed through Steglich esterification [17]. The silanized
and amino-functionalized MNP were dispersed with Ga-DOTA,
DCC and 4-DMAP in dimethylformamide for 24 h at 80 °C in
an ultrasonic bath. DLS measurements showed that the com-
plex was successfully linked to the MNP while the MNP were
not linked to each other. An enlargement of the hydrodynamic
diameter of ca. 67 nm compared to the unsubstituted MNP was
observed (Figure 4 and Table 1).
Figure 4: Diameter of the synthesized MNP.
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TG/DTA measurements detected a weight loss of 9.6% till
100 °C caused by solvent molecules. The weight loss of 46.1%
was caused by the burning organic component in the range of
100 to 550 °C. The unsubstituted MNP were also measured and
compared, in order to demonstrate, that the Ga-DOTA-MNP
had a significant higher organic component (Table 2). Notice-
able is the fact that with increased functionalisation the MNP
get brighter (Figure 5).
Figure 5: MNP after different functionalisation steps.
The particles were washed and dried under the same circum-
stances so that a coloring influence of different solvent
molecules can be foreclosed. Thus the visual input of the
MNP can give a first cautious estimation of a successful func-
tionalization.
Conclusion
In conclusion, Ga-DOTA and [Fe(II)(Cl-bzimpy)2] complexes
were synthesized and linked to magnetic nanoparticles. The
linked MNP were analyzed with DLS and TG/DTA and showed
a significant enlargement of the hydrodynamic diameter com-
pared to the unsubstituted MNP, which is clearly an indication
for a successful conjunction to the Ga-DOTA as well as the
[Fe(II)(Cl-bzimpy)2] complex. The higher weight loss of the
modified MNP detected with TG/DTA confirms a succesful
synthesis of the desired compounds (see Supporting Informa-
tion File 1 for full experimental data). Further synthesis and
studies such as the simultaneously affixing of the mentioned
complexes on the MNP, the labeling with alpha emitters, the
precise pH stability and the behavior of the MNP in a specified
magnetic field are planed.
Supporting Information
Supporting Information File 1
Additional experimental data.
[http://www.beilstein-journals.org/bjnano/content/
supplementary/2190-4286-7-14-S1.pdf]
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